Pod Insights Equity Podcast How Chipiron's rethinking the future of MRI About this episode Medical device funding is hitting levels we haven't seen since 2021, with investors pouring billions into diagnostics and imaging companies. But while innovation has raced ahead, a fundamental problem still hasn't changed: critical medical hardware like MRI machines cost millions of dollars and are gatekept by large hospitals. So how do you take one of the most expensive, hospital-bound technologies and make it available anywhere?
Evan Kervella, founder and CEO of Paris-based startup Chipiron, joined Equity to walk us through the problem and his vision for solving it.
Listen to the full episode to hear about:
The unscalable nature of traditional MRI machines that rely on superconducting magnets and liquid helium.
How Chipiron is building installation ease and patient experience into its scaling mission.
Why Chipiron’s lightweight MRI technology isn’t designed to compete with old school machines.
Longevity movement backers.
Why it’s okay to chase M&A as an exit strategy, especially in the medical industry.
Equity will be back Friday with our weekly news roundup, so stay tuned.
Equity is TechCrunch’s flagship podcast, produced by Theresa Loconsolo, and posts every Wednesday and Friday.
Subscribe to us on Apple Podcasts, Overcast, Spotify and all the casts. You also can follow Equity on X and Threads, at @EquityPod.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Transcript 0:00 Speaker 00 This episode of Equity is brought to you by Schneider Electric. Schneider Electric, advancing energy tech.
0:05 Speaker 01 Hello and welcome back to Equity, TechCrunch's flagship podcast about the business of startups. I'm Rebecca Bala and this is the episode where we bring on industry experts to help us explore a trend in the tech world and dive deep. Medical device funding is hitting levels we haven't seen since 2021, with investors pouring billions into diagnostics and imaging companies. But while innovation has raced ahead, a fundamental problem still hasn't changed. Critical medical hardware, like MRI machines, cost millions of dollars and are gate-kept by large hospitals. So how do you take one of the most expensive, hospital-bound technologies and make it available everywhere? Evan Kurvola, founder and CEO of Paris-based startup Chip Iron, is here to walk us through the problem and his vision for solving it.
0:53 Speaker 01 Evan, welcome to the show.
0:55 Speaker 02 Thank you very much. Thank you for having me.
0:56 Speaker 01 Thank you for having me and thank you in advance for your patience with me. I am under the weather, extremely jet-lagged after coming home from New Zealand last night. So we're gonna, we're gonna have fun though. We're gonna talk about this. I'm really excited.
1:08 Speaker 02 Sure, sure.
1:09 Speaker 01 So, okay, give us a little bit of a background. You've been building Chip Iron since May 2020. Big year for medical everything. You've already won quite a few awards for this technology and for your startup. I'd love to hear more about what your vision is and how far along in the process you are today.
1:26 Speaker 02 Yeah, that's a vast question. So the vision I have is exactly what you're stating. Medical imaging has been at the forefront of the care pathway for a long time already. Each time you have something that starts to be quite complicated, doctors want to see through your body. That makes a ton of sense. MRI is by far the best medical imaging to do so. In the vast majority of cases, of course, there are cases where ultrasound CT scan makes more sense, but vast majority MRI is the best by far. But definitely the most hardly accessible medical imaging technique because it's so expensive, so hard to install, to operate. So that's the modality where you have the least number of machines available. So that's the best one, but the one with the least number of machines. So you can imagine that that's a big bottleneck. When we've started.
2:10 Speaker 02 in 2020 with Dimitri Mykhafonda, we had this vision of solving the problems that explain the lack of accessibility to MRI, building first machine and new generation of machine that wouldn't suffer from the same limitations as big machines. And the reason why it's so exciting and compelling to start a product that solve this problem is that when you dive deep into why MRI is so expensive, so complicated compared to all the modalities, you realize that there is one very well identified root cause that explains all the problems. And this root cause is the fact that today's machines rely on very intense magnetic fields that need to be generated by big superconducting magnets.
2:49 Speaker 02 And these are the magnets that need so much energy, that needs to be cooled down at extremely low temperature by liquid helium, that are very big, that are cumbersome, that are expensive, like everything comes down to that. So basically, the easy story behind Chipiron is that we have started a company that aims to build the first machine that is highly performing while not requiring big superconducting magnets to run. We're building a low magnetic field MRI machine. That's super hard to do because most of the signal that we're using to generate high quality images today directly comes down to the fact that we're using high magnetic field.
3:28 Speaker 02 So we're trying to solve this very complicated physics problem of trying to have high performance while low signal. And all the technological development we've made, all the investments, everything is directed toward solving this hard physics problem.
3:44 Speaker 01 And so you've raised 17 million in series A funding so far?
3:47 Speaker 02 Yeah.
3:48 Speaker 01 Is that correct?
3:49 Speaker 02 Total, it's a total we've passed $23 million in funding total.
3:53 Speaker 01 Okay. And so are you still working on, like, do you have a prototype? Have you already tested this out? Have you been doing clinical trials yet?
3:59 Speaker 02 We've made several iterations of different prototypes. So so far we've done two, each one was an iteration. The first one was the first iteration, the second was a better version of the of the first one with different properties. Now the third one that we're assembling right now in our facility would be the first one where we'll be able to do full body in vivo images. That would be a big step. We'll start doing these images between the end of the year and next summer will be the batch where we're doing internal in vivo images. And we're already building, designing the fourth prototype, which will be deployed in hospital end of next year, so end of 2026. And this one will be the one where we'll start doing some clinical trials.
4:40 Speaker 01 Hmm. Okay. And then is this going into hospitals in in Paris or in Europe? Or are you, which markets are you targeting first?
4:47 Speaker 02 Yeah, so we're 100% US focused. So the the commercial market will be the US, but for the first clinical trials that, I mean, I'm saying clinical trials, but that's more an investigation to just validate the quality of the images and to show what type of in vivo images we can see, what type of diagnosis we can make with our machine on which organs and all of that. This investigation will be done in France because they're just easier, makes more sense. And to interpret medical images, you don't need to have the doctors being based at the same place where images have been taken. So for the this development and investigation in France makes more sense, but the commercial development will be made 100% in the US.
5:27 Speaker 01 I do want to talk about some of the differences between the two markets a little later on, but for now, how much cheaper are you expecting your machines to be to a typical MRI if you have numbers to throw around?
5:39 Speaker 02 Yeah, absolutely. So the easy answer is like 25% ish to what an MRI costs today, but I'm talking about the total cost of ownership. So when you add up all the infrastructure that you need to deploy to install an MRI machine, the electricity that it consumes just to to run. So when you add up all these costs, we're like less than 25% of the total cost of ownership of standard machines. But what is interesting is that price is not really the main bottleneck with today's spread of MRI machines, I would say. It's very much about the complexity to install and operate them. That's what is the the main bottleneck today. And to give you an idea of the big difference between our machines and today's MRI, that today's MRI, that's
6:19 Speaker 02 a one-year-long project between the moment you have the budget and the moment the MRI runs in your hospital. There's a one-year gap because of how long it is to build it, the time it needs to be You just install, you need to destroy the walls of the hospital because it's too big, it cannot go through the doors. You have to have a crane to install rails in the hospital, you have to build back the hospital, you have to, before that, you had to straighten the floor, just because the machine is so heavy on a relatively small surface. You need to shield the room in which you have the machine, like you have all these crazy installations to do beforehand. That's why it's so long. While with our machine, doesn't necessitate any liquid helium, is light, is dissembled,
7:00 Speaker 02 so just arrives in a couple of days, it works, you don't need to install anything beforehand. So it's very much like the huge difference, there will be many, but the main difference, the thing that taught the most to our customers, is really this idea of installing the machine in a couple of days, without having to install anything beforehand, compared to the one year long project with current MRI.
7:20 Speaker 01 Was that a part of your pitch or a part of your, you know, business plan? Like, you know, not just focused on how to solve the problem of making this more cost effective, but also how to solve the problem of being able to scale it by making it not such a pain to to set up?
7:34 Speaker 02 Yeah, absolutely. So during the life of the project, we we have been able to refine with customers, what what really were the core features that were the more, the most interesting, the most important? Because everything seems to be a must have, but of course, when you when you dive deeper and by talking to many, many, many different customers, different geographies, different clinicians and all that, CFOs of hospital, clinicians, MRI technologists, you start getting the real the real signal. And really, I think the the biggest value proposition we have really is about the the efficacy of the installation. Price come come very close, the top three of the core features, of course, but this one is really the game changer. The patient experience is also a big one, as counterintuitive as it may sound.
8:18 Speaker 01 Is it still, is your machine as loud and scary?
8:21 Speaker 02 No, absolutely not. No. You will be in an open room, in the same room where you have the clinician. You will even be able to have your, like, family, whomever friends that are with you during your exam. Think about the child, for example, they can make a big difference for child. There won't be any noise, the machine won't be big, you won't go inside the tunnel, the whole experience would be very different.
8:42 Speaker 01 Interesting. Yeah, I mean, it sounds way better. As you've been trying to innovate in this sector, in medical devices, like, what has surprised you or what have you learned about the industry and willingness to adopt?
8:56 Speaker 02 Yeah. I don't have that much experience with other industries, so I cannot really compare. But what I've realized, and because everyone thinks their industry is very complicated, like more complicated than others. So I don't know what to suffer from this bias. But I think medical imaging and the medical word in general is very conservative, very hard to change practices for one specific reason. The reason is that if we change, it means that what we're doing before were suboptimal, less good. And when you are dealing with people's life, that can be very, very hard. Like the brain puts a lot of protections to avoid having to admit that what you were doing before was wrong.
9:39 Speaker 02 So people can be very defending with the status quo. And with our MRI machine, what we, the value proposition we bring is just more accessibility. But what some doctors will see is that the image quality won't be as good as the best MRI machine that exists today. And that's true. We'll never compete on image quality per se. Like the thinness of the pixels on the image, for sure. Like a seven Tesla MRI machine that costs like three, four, five millions, even more, most of the time, like that takes like 100 square meter of space on the floor to be installed. Like, of course, we won't compete with that. That's not what we bring to the table. What we bring to the table is having MRI in places where you wouldn't rely on MRI
10:24 Speaker 02 today, and that would be better for the patient, actually. Or even like just avoid for the patient to ride for three hours to get to the nearby hospital to get access to the MRI after a month of waiting time.
10:35 Speaker 01 Right. So wait, so it's not the same quality necessarily as those? So it's like MRI light?
10:40 Speaker 02 Yeah, it won't compete. And we don't want to make competition with high field MRI because we know we will lose this competition because radius are very much used, the eyes is very used to the quality that you have with very, very high magnitude field. To give you an idea, we're working with 1% of the signal, the 1% of the magnitude field of today's machine. So just 1% of the signal, you can imagine how hard it is to just compete on the image quality. For sure, for a fact that it's more than enough to put a diagnosis, to make a diagnosis based on the image quality we get. We have tremendous image quality. It's just that, of course, with the highest magnitude devices that you have today, this is not what we're compete against. We don't compete against a high field.
11:23 Speaker 02 We're really compete against no field. That's what we often say. And having this balance is something that we felt, especially at the beginning, when we were trying to make competition with high field MRI naturally, we could feel this resistance from radiologists.
11:39 Speaker 01 Yeah, I mean, I can imagine also, you know, one thing that kind of stuck out to me, especially since you're trying to make this work in the US is, you know, the centralized MRI model works for US hospitals and imaging centers because it's a profit center for them, right? Low-cost distribution scanner can really undercut that model. And, you know, also on the insurance side of things, US reimbursement is pegged to specific equipment standards. You know, this might not have those codes yet, could disincentivize adoption. How are you running up against these kinds of like business level roadblocks?
12:12 Speaker 02 Yeah, so I think every case is in our favor. So there are two cases, the statute clause, the main one, the default one, that is happening at the moment because we already have some competitors in the US that already brought to the markets lower field MRI machines with specific hues, different features, and they fit through the same CPE codes. This default scenario where we have the same CPE codes just means that the clinician, the hospital, the clinic pays a lower price to get the same type of revenue from it. So the ROI is better with the lower field scanner compared to a higher field one. The other scenario where we have different CPE codes, for example, that would be also a blessing for us because it means that it would be very much easier for us
12:56 Speaker 02 to get agreements with healthcare insurance to push our device versus high field scanners for a bunch of different scenarios like screening, you know, that like the beginning, the top of the funnel, where you just need an MRI to check if everything is right. You don't necessarily need a very thin precision in the image quality. In this case, it makes more sense for the healthcare insurance to push this modality because it costs less to give like, we know, the same quality of diagnosis to the clinician. So both scenario work, I think, pretty well for us.
13:29 Speaker 01 It's kind of like the diner model. We've got a quick turnover, high turnover, people coming in for something a little more standard, but you know, does the job versus, you know, fine dining, which is the more intensive, high magnetic MRIs. How are you? So, I mean, we're seeing-
13:45 Speaker 00 What moves our world forward? Energy. History has been shaped by it, revolutions won with it, and progress dependent on it. For 190 years, Schneider Electric has been a leading force in this story, creating the technologies that harness energy and transform the competitive landscape. And today, in the dawning era of energy and industrial intelligence, Schneider is helping customers build more efficient, resilient, and sustainable operations across every sector, from data centers to homes, from buildings to industry. Schneider Electric, your energy technology partner. Discover more at se.com.
14:22 Speaker 01 Funding generally for deep tech and health, you know, med tech, VC investment reached $4.1 billion in the second quarter of 2025, according to PitchBook. The sector's on pace for its second-best year on record, trailing only 2021, which was, you know, just a big year for everything. How are investors viewing this early screening market? And where are most of your investors from? Are they mostly in Europe? Or do you have some in Silicon Valley as well? Both?
14:48 Speaker 02 Yeah, we have both. Most funding came from Europe, surprisingly, but we have investors from the beginning that are based in the US. They really like this type of model of screening, especially in a context where longevity, industry, private healthcare, out-of-pocket screening is starting to get bigger and bigger and takes a bigger and bigger place in people's life. So they think that that's a huge tailwind that we have. There's also something that is very exciting in medical imaging, specifically when it comes to screening, is that that's the perfect ground for AI. If you really, you need to screen super fast, something where you know exactly what you're looking for, and you just need like the biggest bottleneck is on the hardware and on the imaging capability.
15:31 Speaker 02 This would be a huge combo, and that's something I've been like believing in from the very beginning, and it starts to be very clear since like a year. But it's been five years that in my- And like everyone is talking about AI to increase the image quality of like medical images. That was the the biggest application of AI in our field for the past five years. And from the beginning, I'm like, that doesn't make any sense. The huge playground for AI will be on the auto diagnosis side of things, especially in the context of screening.
16:00 Speaker 01 Is that something that you want to bring into your business model or are you sticking with hardware?
16:04 Speaker 02 So we're thinking with hardware. That's the the easy answer. We want to make the best hardware that exists. And we want to deploy as fast as possible. We want to own the distribution channel. I think that would be, that's the most complicated part of the business. When it comes to auto diagnosis AI, there are two scenarios. The first one is that it became like AI became so self sufficient and so like easy to develop because of all the tools that we have in our possession to build our own apps and software. That it will be easy for us to build an auto diagnosis tool that can be put on top of our machine. I don't believe in that because medical images, I mean, you're dealing again with people's life. So having a very strict regulation, background and necessities and roadblocks make a lot of sense.
16:48 Speaker 02 So having it completely automated, don't really believe that. I think that would be a harder business to build. So I believe in the partnership aspect of business more. So doing an exclusive partnership with an AI diagnosis company and to have them bring their their AI on our machines, I think is is what we'll go for.
17:06 Speaker 01 Are you already in talks for these kinds of partnerships or are you shopping?
17:10 Speaker 02 With all the big one, I mean, we're talking with two types of people, the biggest ones. And also the startup that we think have a lot of potential and that are kind of at the beginning with, but with a huge trajectory. That's the type of people we're talking to. That's not urgent at all for us.
17:25 Speaker 01 Right.
17:25 Speaker 02 That would be a big topic in like two years from now, I think. So for the moment, we're just starting the conversations with with everyone.
17:31 Speaker 01 Yeah, okay. Well, if your other founders are listening, you know, they should get in touch if they if they want to do a collab. Well, we're definitely seeing a lot in this, as you mentioned, like the longevity space, the taking control of your own health space, right? Where, you know, I think we spoke on Equity last year about a company called Synex. They do portable MRI for non invasive glucose monitoring.
17:50 Speaker 02 Yeah.
17:50 Speaker 01 They've raised, I mean, last year they raised like twenty two million from COSLA and some seed funding from Sam Altman, who's definitely involved in this space. But there's definitely, it feels like a growing place to to watch for sure.
18:02 Speaker 02 Absolutely.
18:03 Speaker 01 Now, I'm kind of curious, though, how are investors seeing, you know, at the end of the day, you're still doing a hardware as a service in a way, right?
18:10 Speaker 02 Yeah.
18:11 Speaker 01 That's a tough business.
18:12 Speaker 02 Yeah.
18:13 Speaker 01 It's capital intensive, there's not always big margins on that. How are you convincing investors that this is going to give them, especially, you know, VC, that they're going to get the return on investment that they want for this kind of an outlay?
18:28 Speaker 02 Yeah, so the retail investment, is that something that I'm worried about? Because there are different ways to be the high valuation company. Because at the end of the day, that's what interests them. It's not really about the revenue, it's not really about that. It's very much about the valuation of the company, what you can reach. And you have like several examples of medical hardware companies that went to levels that are incredible, the biggest one being Intuitive Surgical. So you have this type of company that we can see what kind of playbook they've run and how they've deployed the company to increase the cash. So there are different answers. The market is huge, growing. We almost will have a monopoly on that because the technology is so hard to develop. We have a patent that protects our technology.
19:13 Speaker 02 We think our technology is the only one that can make it really work at scale. So there are different ways. Of course, the margins and the velocity of the valuation cannot match what you get in AI and software today. So if you are talking to investors that are only interested in this type of deals, but also have a lot of depth in this type of environment, I think we're a safest play, even though that looks like a moonshot. We are developing tangible value. At the end of the day, that's healthcare. There's always need for medical imaging for. So that's a safest bet than just like trying to get into the hottest AI deal of the moment, where you hope you will be able to squeeze a little ROI on the valuation that was already very, very high from the very beginning.
19:56 Speaker 02 We've managed to keep the valuation very, I think we didn't fall for the trap of taking the highest valuation term sheet from the beginning, especially when you were mentioning we started basically in 2021. We consciously did not take the highest valuation term sheet that we got for our. which would have put us in a very different space for the rest and would be even harder to to start to justify the the newest valuation for the so I think we had a lot of cash discipline, valuation discipline. The medical hardware brings tangible value, so it's a safe bet. And you have different medical hardware companies that shown how you can reach the hundred of billions of valuation. So we'll just follow their steps on this.
20:37 Speaker 01 Yeah, interesting that you mentioned that about the term sheets like I'm sure, you know, startups are always raising. So I'm not sure if in this fundraising environment at the moment in 2025 for AI, I imagine it's kind of like 2021. There's these out of control term sheets, but I'm wondering for, you know, your industry, is it back down to earth for the most part?
20:55 Speaker 02 Yeah, definitely, definitely. Indeed, there is, I have read these incredible stats that I think like 41%. I think that's the of all the cash that has been invested since 2025, I think, to be verified what was the period. But right now, 41% of all US VC funding in 10 rounds since the beginning of the year, I think. So yeah, that's that's the type of environment for AI and all craziness that you're mentioning. Much more down to earth in our case, which is not a bad thing. I mean, I'm not judging that. I don't put any any value around that. What matters to me is that the cap table is very solid and that we get the money that we need, you know, to reach the next milestone. And that's how we've been thinking about it from the beginning.
21:37 Speaker 01 How are you thinking about long term exit strategy, right? Like we've had, we've seen, you know, Aura has acquired metabolic health startup Very, Function Health bought Ezra, which has a full body scan for a third of the price. Are you trying to take this home or are you open to some kind of acquisition to help you get it off the ground and advance the technology even further?
21:58 Speaker 02 Yeah, when I look at the different stories you have in medical imaging, in most cases, like most of the successful story went through an acquisition. That's really how you grow and how you get access to the distribution channel. I was mentioning that at the beginning. Distribution channels in medical hardware is very tough because that's long relationships, long sales cycles. Some hospitals are gate kept by these big institutions, the big incumbents. Field. So going through an acquisition is definitely, I think, would be a huge success. What we need to make that a possibility is that we show them the evidences, the clinical evidences and the market evidences that what we're doing is is going to be a success. And in this case, that's pretty straightforward. We're already in conversation with all of them, of course.
22:44 Speaker 02 But we know exactly what they want to see and that's the direction. Anyway, that's that's the same direction as if we want to bring that home and do an IPO ourselves. Goes through showing the clinical evidences that it works, then showing the market traction that shows that people want the machine. And then showing the manufacturing capability and the fact that you start having the assembly line that will be able to deliver the number of machine that you've pre-sold, that you you have a waiting list for, and then showing that you have the sales capacity. So anyway, that's that's the same, that's the playbook for success.
23:14 Speaker 01 Either way, you gotta put your head down, do the business, make it make it sustainable. Yeah, for sure. And then, you know, another thing I wanted to touch on with you because I noticed on your website, there's a lot of hiring materials and we spoke as we joined, you talked about that you're still doing interviews, it doesn't actually come naturally to you, because you'd probably rather be building. But how are you finding looking for talent? And are you noticing that you have to compete with AI companies? I mean, it's different, it's a different industry, but there's a lot of I think that AI is kind of touching a lot of different industries at this moment. So it might be difficult to compete for talent or how are you finding it?
23:49 Speaker 02 I I don't really see that because for AI engineers and full stack developers, for example, for sure. You see that there is like huge competition and salaries are crazy. We see that less from France than if we're based in the in the Bay. That's for sure. For other like electronics engineers, hardware leads, all these different positions, we see less these things.
24:10 Speaker 01 Yeah, those I'd be imagining would be going into like robotics, maybe, or like physical AI.
24:15 Speaker 02 AI, okay, okay, that's right. But most of the people, when you start in the medical field, especially in the medical device field, most people, they didn't happen to be there. It it made sense for them. It resonated with the meaning they wanted to put behind their career. So most of the people that start in medical device, they In medical device, I think that's something that protects us and and give us a protected pool of talent. On the second half of your question about finding talent and all of that, that's that's a tough one. It did I spend a lot of time interviewing people trying to like most of the the awards that we try to get compete. Most of them are not to find investors because investors are quite easy to find, then you got to seduce them.
24:58 Speaker 02 And most of the time, winning awards, being unseen, I didn't find that very compelling thing for a startup like. If if I were a VC, if I were an investor, I wouldn't be hyped because the company won an award, all of that. That's interesting because you're like, OK, they are on my list, I'm interested to talk to them. But what will really interest me is their numbers, like the velocity of the R and D, what say the K O L in your industry about what you're doing? Is that impressive if I talk to the different founders? Are they all super, super strong? Is the vision compelling? Does the market make sense? The business plan? All that are far more important things. But for talents, you have like, you don't know, like all the VC funds that are lists, but they are not lists of all the talents
25:41 Speaker 02 that exist in the specific industry or role that you try to hire. So the I spent a lot of time on the brand awareness, trying to win awards, prices, try to show that we're very solid. And this is the type of stuff that's on a long period of time, like just one award, one conference, doesn't make the difference. But on the long run, after five years, I have tremendous inbound of great people like, yeah, my father told me about your company because he read in the journal. Or, yeah, I saw you on the T V a year ago and then I thought about it. That I I really tried to put myself in the shoes of other people who want to hire. So this and spending a lot of time interviewing because you want to.
26:21 Speaker 02 And and what's really hard is that you don't know exactly, I mean, me specifically, I'm very humble when it comes to like being a C E O in general, but especially in interviewing. You have a ton of bias. You know that the person is trying to tell you what you need, what you want to answer. Like there are so many filters, like communication in itself is hard, but in the context of an interview, that's even harder. So trying to get to the bottom of who the person is, what they want, are they here for the long run, do they fit with the company's value? That's the type of thing I'm trying to assess and I know it takes a lot of volume. I really believe in volume as the answer to most of the challenges. So yeah, just volume and having great brand and working with the best hiring consultants
27:06 Speaker 02 and using all the AI tools that you can.
27:09 Speaker 01 Yeah.
27:09 Speaker 02 To find the talent that you want.
27:12 Speaker 01 Yeah, well, two things on that. One is on your awards. We forgot to mention, but you guys won the Innovation of the Year Award at Beavitec 2025, got first place out of 600 startups awarded by TechCrunch. And on the second thing, I actually have, I'm trying to remember if I've talked about this on Equity or if there's an interview that I did with a founder. One of their pieces of advice for other founders was to hire someone to hire people for you if you can trust, because it's like, it's just like a whole lot of admin for you to do as a founder and CEO who's busy doing other things and trying to make the business work. And it actually takes so much time that could be spent on more important things. So anyway, if that piece of advice is helpful to you
27:55 Speaker 01 or other founders listening, I am happy. But that probably brings us to the end of our show. So Evan, thank you so much for joining us. Where can our listeners find you, try to collab with you, try to invest in you online?
28:10 Speaker 02 Yeah. Thank you very much for having me. It was a great conversation. Thank you for the quality of your question. People can find us on, I mean, mostly on LinkedIn, I think is the, is the way to reach out. And I'm always reachable to [email protected] . So on the website, it's written everywhere. You can contact us from our website, chipiron.co, or LinkedIn, me, Evan Carvajal, the company Chipiron. Reading everything, mostly answering to everyone, especially, I mean, except for very obvious outbound.
28:40 Speaker 02 Salespeople trying to sell me something, but otherwise if you're someone that has like genuine questions about the company, talent trying to join, want to reach out, I'm always, always answering, open to discuss with everyone because I know that there are many things that I don't know, that I don't know. So I try to reduce the darkness in my mind.
29:00 Speaker 01 Yes, I know I'm intelligent because I know I know nothing. Socrates, I think.
29:03 Speaker 02 Exactly.
29:03 Speaker 01 Anyway, for those who don't have a French register to their ear, that's [email protected] . For those who don't remember where to find us, our listeners, you can find Equity at EquityPod on Blue Sky and X. You can find me on the same platforms. Talk to you next time.
29:22 Speaker 03 Equity is hosted by TechCrunch senior reporters and produced by Teresa Locan Solo with editing by Kel. Subscribe wherever you get your podcasts and see what's next at techcrunch.com/events. Thanks so much for listening and we'll talk to you next time.
Previous Live demo fails, AI safety wins, and the Golden Age of Robotics Next From $100B OpenAI deals to $100K visa fees Page updated October 26, 2026 · transcript and summary are machine-generated